Aslani A - Search Results

1

Overlooked potential of positrons in cancer therapy.

Hioki T, Gholami YH, McKelvey KJ, Aslani A, Marquis H, Eslick EM, Willowson KP, Howell VM, Bailey DL. Hioki T, et al. Among authors: aslani a. Sci Rep. 2021 Jan 28;11(1):2475. doi: 10.1038/s41598-021-81910-4. Sci Rep. 2021. PMID: 33510222 Free PMC article.

2

In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging.

Bailey DL, Hennessy TM, Willowson KP, Henry EC, Chan DL, Aslani A, Roach PJ. Bailey DL, et al. Among authors: aslani a. EJNMMI Phys. 2015 Dec;2(1):20. doi: 10.1186/s40658-015-0123-2. Epub 2015 Sep 17. EJNMMI Phys. 2015. PMID: 26501821 Free PMC article.

3

In Vivo Measurement and Characterization of a Novel Formulation of [¹⁷⁷Lu]-DOTA-Octreotate.

Bailey DL, Hennessy TM, Willowson KP, Henry EC, Chan DL, Aslani A, Roach PJ. Bailey DL, et al. Among authors: aslani a. Asia Ocean J Nucl Med Biol. 2016 Winter;4(1):30-37. doi: 10.7508/aojnmb.2016.04.005. Asia Ocean J Nucl Med Biol. 2016. PMID: 27904871 Free PMC article.

4

RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics.

Bailey DL, Sabanathan D, Aslani A, Campbell DH, Walsh BJ, Lengkeek NA. Bailey DL, et al. Among authors: aslani a. Asia Ocean J Nucl Med Biol. 2021 Winter;9(1):1-8. doi: 10.22038/AOJNMB.2020.51714.1355. Asia Ocean J Nucl Med Biol. 2021. PMID: 33392343 Free PMC article.

5

Gallium-68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience.

Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Roach PJ. Aslani A, et al. Asia Ocean J Nucl Med Biol. 2014 Fall;2(2):75-86. Asia Ocean J Nucl Med Biol. 2014. PMID: 27408863 Free PMC article.

6

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System.

Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Pavlakis N, Roach PJ. Aslani A, et al. Asia Ocean J Nucl Med Biol. 2015 Summer;3(2):107-15. Asia Ocean J Nucl Med Biol. 2015. PMID: 27408890 Free PMC article.

7

Long-term changes in body composition after pancreaticoduodenectomy.

Aslani A, Roach PJ, Smith RC. Aslani A, et al. ANZ J Surg. 2012 Mar;82(3):173-8. doi: 10.1111/j.1445-2197.2011.05970.x. Epub 2012 Jan 19. ANZ J Surg. 2012. PMID: 22510129 Clinical Trial.

8

Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.

Aslani A, Gill AJ, Roach PJ, Allen BJ, Smith RC. Aslani A, et al. HPB (Oxford). 2010 Jun;12(5):325-33. doi: 10.1111/j.1477-2574.2010.00171.x. HPB (Oxford). 2010. PMID: 20590908 Free PMC article.

9

Changes in body composition during breast cancer chemotherapy with the CMF-regimen.

Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. Aslani A, et al. Breast Cancer Res Treat. 1999 Oct;57(3):285-90. doi: 10.1023/a:1006220510597. Breast Cancer Res Treat. 1999. PMID: 10617305

10

The predictive value of body protein for chemotherapy-induced toxicity.

Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. Aslani A, et al. Cancer. 2000 Feb 15;88(4):796-803. doi: 10.1002/(sici)1097-0142(20000215)88:4<796::aid-cncr10>3.0.co;2-p. Cancer. 2000. PMID: 10679649

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

214 results

Search Page